Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist studied for its effects on body weight, blood sugar regulation, appetite, and energy metabolism.
It is a laboratory-made peptide designed to activate three hormone receptors at the same time: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
GIP and GLP-1 are involved in insulin signaling, appetite, and the body's response to food. Glucagon is best known for its role in blood sugar regulation, but glucagon receptor activity may also influence energy expenditure and how the body uses stored fuel. Combining all three pathways has made retatrutide an important subject of metabolic research.
What Has Retatrutide Research Studied?
Research on retatrutide has expanded rapidly from early metabolic studies into large Phase 3 clinical trials examining body weight, blood sugar, liver fat, joint symptoms, sleep apnea, and other obesity-related conditions.
- Body weight: Phase 2 and Phase 3 studies have reported substantial average reductions in body weight across several populations.
- Blood sugar regulation: Studies involving people with type 2 diabetes have reported reductions in HbA1c along with changes in body weight and other metabolic markers.
- Liver fat: A dedicated substudy found large reductions in liver fat among participants with metabolic dysfunction-associated steatotic liver disease.
- Metabolic markers: Researchers have examined changes in blood pressure, cholesterol, triglycerides, insulin sensitivity, and waist circumference.
- Obesity-related conditions: Phase 3 research has also examined knee osteoarthritis pain, obstructive sleep apnea, cardiovascular disease, and other conditions associated with obesity.
How Does Retatrutide Work?
Retatrutide activates GIP, GLP-1, and glucagon receptors within a single molecule.
GIP and GLP-1 signaling can help stimulate insulin release when blood sugar rises after eating. These pathways also communicate with areas of the brain involved in hunger, fullness, and food intake.
Glucagon adds a third metabolic pathway. In addition to its well-known role in maintaining blood glucose, glucagon signaling may influence fat metabolism, substrate use, and energy expenditure.
Researchers are studying whether combining these three signals affects energy balance differently than compounds that target GLP-1 alone or GIP and GLP-1 together.
What Has Research Found About Body Weight?
Body-weight change has been one of the most closely followed areas of retatrutide research.
In an earlier Phase 2 trial, participants receiving the highest studied dose experienced an average body-weight reduction of approximately 24.2 percent after 48 weeks, compared with approximately 2.1 percent in the placebo group.
More recent Phase 3 research has reported larger reductions over longer study periods.
In the TRIUMPH-1 trial, adults with obesity or overweight and at least one weight-related condition who received the highest studied dose experienced an average body-weight reduction of approximately 28.3 percent after 80 weeks.
Participants with a starting BMI of 35 or greater who continued into a study extension reached an average reduction of approximately 30.3 percent after 104 weeks.
These are among the largest average weight changes reported in clinical research involving incretin-based compounds. However, differences in study populations, duration, doses, and trial design make direct comparisons between separate studies imperfect.
What Has Research Found About Blood Sugar?
Retatrutide has also been studied extensively in people with type 2 diabetes.
Phase 3 research has reported meaningful reductions in HbA1c along with substantial changes in body weight. In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes receiving the highest studied dose experienced an average body-weight reduction of approximately 20.8 percent over 80 weeks, along with improvements in glucose control.
Other clinical research has reported HbA1c reductions of approximately two percentage points in some study populations.
These findings reflect the combined influence of GIP and GLP-1 signaling on insulin release and glucose regulation, together with changes in food intake, body weight, and metabolic function.
Retatrutide and Liver Fat Research
Liver fat has become another important area of retatrutide research.
A randomized Phase 2a substudy examined participants with metabolic dysfunction-associated steatotic liver disease and elevated liver fat.
After 24 weeks, the two highest studied doses produced average relative liver-fat reductions of approximately 81 to 82 percent. At 48 weeks, the highest dose was associated with an average reduction of approximately 86 percent.
At the higher studied doses, most participants reached liver-fat levels below the threshold commonly used to define hepatic steatosis.
Researchers also found that reductions in liver fat were strongly associated with reductions in body weight and waist circumference, suggesting that several metabolic changes may be occurring together.
What Has Research Found About Knee Osteoarthritis?
Retatrutide has also been studied in people with obesity and knee osteoarthritis.
In the Phase 3 TRIUMPH-4 trial, participants receiving the highest studied dose experienced an average body-weight reduction of approximately 28.7 percent over 68 weeks.
The study also reported substantial improvements in knee pain and physical function. These findings have increased research interest in how large changes in body weight and metabolic health may influence mechanical and inflammatory conditions associated with obesity.
What Has Research Found About Other Metabolic Markers?
Clinical studies have examined a variety of metabolic and cardiovascular markers alongside changes in body weight.
Researchers have reported changes in blood pressure, triglycerides, cholesterol levels, waist circumference, insulin sensitivity, and glucose regulation.
Phase 3 studies have also included populations with established cardiovascular disease and obstructive sleep apnea, allowing researchers to examine retatrutide across several conditions that frequently occur alongside obesity and metabolic dysfunction.
What Has Safety Research Reported?
The most frequently reported effects in retatrutide clinical trials have involved the gastrointestinal system.
These include nausea, diarrhea, constipation, vomiting, and decreased appetite. As with other compounds that influence incretin receptors, these effects have generally occurred more often at higher studied doses and during periods of increasing exposure.
In the Phase 3 TRIUMPH-1 trial, nausea was reported in approximately 29 to 42 percent of participants receiving retatrutide, depending on dose. Diarrhea, constipation, and vomiting were also commonly reported.
Researchers have additionally monitored changes in skin sensation known as dysesthesia. In TRIUMPH-1, dysesthesia was reported in approximately 5 percent of participants at the lower studied dose and 13 percent at the highest dose. Most reported cases were mild to moderate.
Earlier Phase 2 research also identified dose-related increases in heart rate that peaked during the study and declined later in treatment. Cardiovascular measurements continue to be followed in larger and longer clinical trials.
Ongoing research continues to expand the available information about retatrutide across different populations and study durations.
How Does Retatrutide Compare With Other Metabolic Compounds?
| Compound | Primary Receptor Activity | Weight Change Reported in Major Trials |
|---|---|---|
| Retatrutide | GIP + GLP-1 + glucagon | Approximately 28% average reduction at 80 weeks in TRIUMPH-1; approximately 30% in an extended-study subgroup at 104 weeks |
| Tirzepatide | GIP + GLP-1 | Approximately 21% average reduction at the highest studied dose in SURMOUNT-1 |
| Semaglutide | GLP-1 | Approximately 15% average reduction in STEP 1 |
The main biological difference between these compounds is the number and type of receptors they activate.
Semaglutide primarily targets GLP-1 receptors. Tirzepatide combines GIP and GLP-1 activity. Retatrutide adds glucagon receptor activity to both of those pathways.
Clinical trials of retatrutide have reported larger average body-weight reductions than those reported in major earlier trials of semaglutide and tirzepatide. These figures come from different clinical trials, however, so they should not be interpreted as a direct head-to-head comparison.
Why Is Retatrutide of Research Interest?
Retatrutide represents an important development in research on multi-receptor metabolic compounds.
Rather than focusing on a single appetite or glucose-regulating pathway, it combines signaling through three receptors involved in food intake, insulin activity, energy balance, and fuel metabolism.
Research has examined its effects on body weight, glucose regulation, liver fat, lipid markers, blood pressure, joint symptoms, sleep apnea, and broader metabolic health.
The growing body of Phase 3 data is also helping researchers better understand how adding glucagon receptor activity may change the metabolic effects produced by GIP and GLP-1 signaling alone.
Research Sources
- TRIUMPH Phase 3 clinical trials examining retatrutide and body weight
- New England Journal of Medicine Phase 2 obesity research
- Nature Medicine research examining retatrutide and liver fat
- Clinical research examining blood sugar and metabolic markers
- TRIUMPH-4 research involving obesity and knee osteoarthritis
- Ongoing Phase 3 research into triple GIP, GLP-1, and glucagon receptor signaling